Literature DB >> 29435919

The MicroRNA.

Shao-Yao Ying1, Donald C Chang2, Shi-Lung Lin3.   

Abstract

MicroRNAs (miRNAs), widely distributed, small regulatory RNA genes, target both messenger RNA (mRNA) degradation and suppression of protein translation based on sequence complementarity between the miRNA and its targeted mRNA. Different names have been used to describe various types of miRNA. During evolution, RNA retroviruses or transgenes invaded the eukaryotic genome and were inserted itself in the noncoding regions of DNA, conceivably acting as transposon-like jumping genes, providing defense from viral invasion and fine-tuning of gene expression as a secondary level of gene modulation in eukaryotes. When a transposon is inserted in the intron, it becomes an intronic miRNA, taking advantage of the protein synthesis machinery, i.e., mRNA transcription and splicing, as a means for processing and maturation. MiRNAs have been found to play an important, but not life-threatening, role in embryonic development. They might play a pivotal role in diverse biological systems in various organisms, facilitating a quick response and accurate plotting of body physiology and structures. Based on these unique properties, manufactured intronic miRNAs have been developed for in vitro evaluation of gene function, in vivo gene therapy, and generation of transgenic animal models. The biogenesis of miRNAs, circulating miRNAs, miRNAs and cancer, iPSCs, and heart disease are presented in this chapter, highlighting some recent studies on these topics.

Entities:  

Keywords:  Biogenesis; Cancer; Circulating miRNA; Drug development; Heart disease; Intronic miRNA; Mechanism; Noncoding RNAs; Small RNA; Transposons; iPSCs; miRNA; siRNA

Mesh:

Substances:

Year:  2018        PMID: 29435919     DOI: 10.1007/978-1-4939-7601-0_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  MiR-508-3p promotes proliferation and inhibits apoptosis of middle ear cholesteatoma cells by targeting PTEN/PI3K/AKT pathway.

Authors:  Dongliang Liu; Xiulan Ma
Journal:  Int J Med Sci       Date:  2021-07-11       Impact factor: 3.738

2.  miR-223-3p inhibits the progression of atherosclerosis via down-regulating the activation of MEK1/ERK1/2 in macrophages.

Authors:  Daofeng You; Qiuge Qiao; Katsushige Ono; Mei Wei; Wenyun Tan; Cuihua Wang; Yangong Liu; Gang Liu; Mingqi Zheng
Journal:  Aging (Albany NY)       Date:  2022-02-24       Impact factor: 5.682

3.  Exploring Relevant mRNAs and miRNAs in Injured Urethral Tissues of Rats with High-Throughput Sequencing.

Authors:  Han Lin; Shiyong Guo; Song Li; Jihong Shen; Jianfeng He; Yun Zheng; Zhenhua Gao
Journal:  Genes (Basel)       Date:  2022-05-05       Impact factor: 4.141

4.  miR-1, miR-499 and miR-208 are sensitive markers to diagnose sudden death due to early acute myocardial infarction.

Authors:  Enrica Pinchi; Paola Frati; Mariarosaria Aromatario; Luigi Cipolloni; Matteo Fabbri; Raffaele La Russa; Aniello Maiese; Margherita Neri; Alessandro Santurro; Matteo Scopetti; Rocco Valerio Viola; Emanuela Turillazzi; Vittorio Fineschi
Journal:  J Cell Mol Med       Date:  2019-06-26       Impact factor: 5.310

5.  miR-107 is involved in the regulation of NEDD9-mediated invasion and metastasis in breast cancer.

Authors:  Jiamin Zhou; Xianglin Sun; Xinyu Zhang; Huan Yang; Zhenglin Jiang; Qianqian Luo; Yifei Liu; Guohua Wang
Journal:  BMC Cancer       Date:  2022-05-12       Impact factor: 4.638

6.  Sertoli-Leydig cell tumor in two siblings with DICER1 syndrome: A case report and literature review.

Authors:  Ying Zhang; Meng Ren; Yazhen Hong; Yanping Zhong; Xiaofeng Cong; Chen Chen; Ziling Liu; Yu Man; Lei Yang
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

7.  Dysregulated circulating microRNA-126 in chronic obstructive pulmonary disease: linkage with acute exacerbation risk, severity degree, and inflammatory cytokines.

Authors:  Congying Wang; Dong Feng; Shanfeng Dong; Ruilian He; Bosheng Fan
Journal:  J Clin Lab Anal       Date:  2022-01-21       Impact factor: 3.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.